News Column

New Data from General Hospital Illuminate Findings in Non-Small Cell Lung Cancer (Aquaporin 3 knockdown suppresses tumour growth and angiogenesis in...

August 20, 2014



New Data from General Hospital Illuminate Findings in Non-Small Cell Lung Cancer (Aquaporin 3 knockdown suppresses tumour growth and angiogenesis in experimental non-small cell lung cancer)

By a News Reporter-Staff News Editor at Biotech Week -- Researchers detail new data in Oncology. According to news reporting from Beijing, People's Republic of China, by NewsRx journalists, research stated, "Non-small cell lung cancer (NSCLC) is one of the most common diseases encountered in medical oncology practice. The aim of the present study was to test the antitumour effects of short-hairpin RNA targeting aquaporin 3 (AQP3) in experimental NSCLC."

The news correspondents obtained a quote from the research from General Hospital, "Expression of AQP3 was suppressed in human A549 and H1299 NSCLC cell lines by short-hairpin RNA-mediated silencing. Therapeutic effects were assessed by examining tumorigenicity using a subcutaneous xenograft mouse model of NSCLC. Aquaporin 3 knockdown inhibited tumour growth and prolonged survival of mice with tumours. Aquaporin 3 knockdown suppressed tumour proliferation, marked by enhanced expression of p53, an increased ratio of cleaved caspase 3 to pro-caspase 3 and reduced expression of proliferating cell nuclear antigen and B-cell lymphoma-2 (bcl-2). Aquaporin 3 knockdown inhibited tumour angiogenesis, marked by decreased CD31 immunostaining and reduced expression of hypoxia-inducible factor-2a and vascular endothelial growth factor. Aquaporin 3 knockdown reduced cellular glycerol content and suppressed mitochondrial ATP formation. Aquaporin 3 knockdown in vitro significantly suppressed activities of matrix metalloproteinases MMP2 and MMP9, reduced AKT phosphorylation and decreased cell invasiveness of A549 and H1299 cells."

According to the news reporters, the research concluded: "AQP3 knockdown suppressed tumour growth and reduced angiogenesis in human NSCLS xenografts. Aquaporin 3 could thus be envisaged as a novel therapeutic target for NSCLC."

For more information on this research see: Aquaporin 3 knockdown suppresses tumour growth and angiogenesis in experimental non-small cell lung cancer. Experimental Physiology, 2014;99(7):974-984. Experimental Physiology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Experimental Physiology - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1469-445X)

Our news journalists report that additional information may be obtained by contacting H. Xia, PLA, General Hospital, Affiliated Hosp 1, Dept. of Cardiothorac Surg, Beijing 100048, People's Republic of China. Additional authors for this research include Y.F. Ma, C.H. Yu, Y.J. Li, J. Tang, J.B. Li, Y.N. Zhao and Y. Liu (see also Oncology).

Keywords for this news article include: Asia, Beijing, Caspase, Oncology, Aquaporins, Angiogenesis, Lung Neoplasms, Carrier Proteins, Membrane Proteins, Enzymes and Coenzymes, Membrane Glycoproteins, People's Republic of China, Non-Small Cell Lung Cancer, Membrane Transport Proteins

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters